Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06745284
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 465
- Registration Number
- NCT06717698
- Locations
- 🇺🇸
N America Res Inst - San Dimas, San Dimas, California, United States
🇺🇸NorCal Endocrinology and Internal Medicine, San Ramon, California, United States
🇺🇸Northeast Research Institute, Saint Augustine, Florida, United States
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT06699329
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
Evaluation of Semaglutide in Adults with Cocaine Use Disorder with and Without HIV
- Conditions
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 40
- Registration Number
- NCT06691243
Semaglutide for Helping Opioid Recovery
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT06639464
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 370
- Registration Number
- NCT06633783
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳Xuancheng People's Hospital, Xuancheng, Anhui, China
🇨🇳Huizhou Central People's Hospital, Huizhou, Guangdong, China
Semaglutide and Intestinal Iron Absorption
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University Hospital Dubrava
- Target Recruit Count
- 51
- Registration Number
- NCT06629688
- Locations
- 🇭🇷
University hospital Dubrava, Zagreb, Croatia
Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 23
- Registration Number
- NCT06608433
Semaglutide in Treatment of Obesity
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-12
- Target Recruit Count
- 462
- Registration Number
- NCT06604624
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 126
- Registration Number
- NCT06582875
- Locations
- 🇺🇸
University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.